Country: Armenía
Tungumál: enska
Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
ciprofloxacin
Farmalabor - Produtos Farmaceuticos
J01MA02
ciprofloxacin
500mg
tablets film-coated
(1), (8/1x8/) and (16/2x8/) in blister
Prescription
Registered
2021-06-29
PACKAGE LEAFLET: INFORMATION FOR THE USER CIPROFLOXACIN DEMIPHARM 500 mg film-coated tablets Ciprofloxacin Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others; it may harm them even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist. IN THIS LEAFLET: 1. What Ciprofloxacin Demipharm is and what it is used for 2. Before you use Ciprofloxacin Demipharm 3. How to use Ciprofloxacin Demipharm 4. Possible side effects 5. How to store Ciprofloxacin Demipharm 6. Further information 1. WHAT CIPROFLOXACIN DEMIPHARM IS AND WHAT IT IS USED FOR Ciprofloxacin Demipharm is an antibiotic belonging to the fluoroquinolone family. The active substance is ciprofloxacin. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria. ADULTS Ciprofloxacin Demipharm is used in adults for the treatment of the following bacterial infections: - respiratory tract infections - long-lasting or recurring ear or sinus infections - urinary tract infections - infections of the testicles - genital tract infections in women - gastro-intestinal tract infections and intra-abdominal infections - skin and soft tissue infections - bone and joint infections - to treat infections in patients with a very low white blood cell count (neutropenia) - to prevent infections in patients with a very low white blood cell count (neutropenia) - to prevent infections due to the bacterium _Neisseria meningitidis_ - anthrax inhalation exposure If you have a severe infection or an infection caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Ciprofloxacin Demipharm. CHILDREN AND ADOLESCENTS Ciprofloxacin Demipharm is used in c Lestu allt skjalið
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ciprofloxacin Demipharm, 500 mg, film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION COMPOSITION PER TABLET: CIPROFLOXACIN DEMIPHARM Active substance: Ciprofloxacin (as hydrochloride) 500.0 mg Excipients: Lactose 48 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Ciprofloxacin Demipharm, 500 mg, film-coated tablets: White, oblong, biconvex coated tablets, scored on both sides. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ciprofloxacin Demipharm film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to the available information on resistance to ciprofloxacin before initiating treatment. Consideration should be given to official guidance on the appropriate use of antibacterial agents. ADULTS - Lower respiratory tract infections caused by Gram-negative bacteria: . exacerbation of chronic obstructive pulmonary disease; . broncho-pulmonary infections in cystic fibrosis or bronchiectasis; . pneumonia. - Chronic suppurative otitis media. - Acute exacerbation of chronic sinusitis especially if caused by Gram-negative bacteria. - Urinary tract infections. - Gonococcal urethritis and cervicitis. - Epididymo-orchitis including cases due to _Neisseria gonorrhoeae_. - Pelvic inflammatory disease including cases due to _Neisseria gonorrhoeae_. When it is suspected or known that the aforementioned genital tract infections are due to _Neisseria _ _gonorrhoeae_, it is particularly important to obtain local information on the prevalence of resistance to ciprofloxacin and to confirm susceptibility, based on laboratory tests. - Gastrointestinal tract infections (e.g. traveller's diarrhoea). - Intra-abdominal infections. - Infections of the skin and soft tissue caused by Gram-negative bacteria. - Malignant external otitis. - Infections of the bones and joints. - Treatment of infections in neutropenic patients. - Prophy Lestu allt skjalið